Formulation: A solution in methyl acetate
Formal Name: (Z)-7-((1R,2R,3S,5S)-3,5-dihydroxy-2-(3-oxooctyl-5,5,6,6,7,7,8,8,8-d9)cyclopentyl)hept-5-enoic acid
Purity: ≥99% deuterated forms (d1-d9)
Formula Markup: C20H25D9O5
Formula Weight: 363,5
Shelf life (days): 365
CAS Number: 2738376-88-8
Notes: 11β-13,14-dihydro-15-keto Prostaglandin F2α-d9 (11β-13,14-dihydro-15-keto PGF2α-d9) is intended for use as an internal standard for the quantification of 11β-13,14-dihydro-15-keto PGF2α (Item No. 16540) by GC- or LC-MS. 11β-13,14-dihydro-15-keto PGF2α is a metabolite of prostaglandin D2 (PGD2; Item No. 12010) in the 15-hydroxy PGDH pathway.{11174,11176} Infusion or inhalation of tritiated PGD2 in normal males results in the appearance of peak levels of both 11β-PGF2α, as the immediate product, and 11β-13,14-dihydro-15-keto PGF2α in the plasma within 10 minutes.{11174} Homogenates of human lung metabolize PGD2 first to 11β-PGF2α and then to 11β-15-keto-PGF2α in the presence of NAD+, but not 11β-13,14-dihydro-15-keto PGF2α.{11176} Guinea pig liver and kidney homogenates metabolize PGD2 to 11β-13,14-dihydro-15-keto PGF2α, via 11β-PGF2α, in the presence of NAD+ and NADP+.{11176}